1. Short title This Act may be cited as the Charles Rochester Blood Clot Prevention and Treatment Act . 2. Findings Congress finds the following: (1) Deep venous thrombosis (in this Act referred to as DVT ) occurs when blood clots form in the legs, pelvis, or arms, and the most serious complications occur when a part of the clot breaks off and travels to the lungs, causing a blockage called pulmonary embolism (in this Act referred to as PE ). (2) According to the Centers for Disease Control and Prevention, 1 American dies every 6 minutes as a result of a blood clot, and 1 in 4 people who have a PE die without warning. (3) The Centers for Disease Control and Prevention has estimated that about 900,000 people suffer from DVT/PE per year and 100,000 people die each year from blood clots, but also recognizes that the precise number of people affected by DVT/PE is unknown. (4) These numbers are estimated because currently there is no systematic collection of DVT/PE-related morbidity or mortality data in the United States. (5) Blood clots can affect anyone, but certain risk factors make certain individuals more susceptible, including pregnancy, cancer, hospitalizations, obesity, older age, and African American race. (6) The overall incidence of DVT and PE is 30 to 60 percent higher in Black Americans, who also have a higher rate of 30-day mortality compared with White Americans. (7) The direct and indirect cost of blood clots is more than $10,000,000,000 annually. (8) Early diagnosis of a DVT is one of the most important factors in preventing a PE. 3. Public education, awareness, and diagnosis of DVT/PE Part J of title III of the Public Health Service Act ( 42 U.S.C. 280b et seq. ) is amended by inserting after section 393D the following: 393E. Prevention of morbidity and mortality as a result of deep venous thromboembolism (a) In general The Secretary, acting through the Director of the Centers for Disease Control and Prevention, (in this section referred to as the Secretary ) shall carry out projects to increase